☰

Istvan Bitter - Publications

Affiliations: 
Semmelweis Egyetem, Hungary 
Area:
Pharmacy, Clinical Psychology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

102/231 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Papp S, Tombor L, Kakuszi B, Réthelyi JM, Bitter I, Czobor P. Electrophysiological underpinnings of dysfunctional inhibitory control in adults with attention-deficit/hyperactivity disorder: evidence for reduced NoGo anteriorization. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 37131048 DOI: 10.1007/s00702-023-02639-0  0.335
2020 Papp S, Tombor L, Kakuszi B, Balogh L, Réthelyi JM, Bitter I, Czobor P. Impaired early information processing in adult ADHD: a high-density ERP study. Bmc Psychiatry. 20: 292. PMID 32522183 DOI: 10.1186/S12888-020-02706-W  0.387
2020 Baradits M, Bitter I, Czobor P. Multivariate patterns of EEG microstate parameters and their role in the discrimination of patients with schizophrenia from healthy controls. Psychiatry Research. 288: 112938. PMID 32315875 DOI: 10.1016/J.Psychres.2020.112938  0.345
2020 Kakuszi B, Szuromi B, Bitter I, Czobor P. Attention deficit hyperactivity disorder: Last in, first out - delayed brain maturation with an accelerated decline? European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 34: 65-75. PMID 32279924 DOI: 10.1016/J.Euroneuro.2020.03.011  0.386
2020 Arteaga-Henríquez G, Rosales-Ortiz SK, Arias-Vásquez A, Bitter I, Ginsberg Y, Ibañez-Jimenez P, Kilencz T, Lavebratt C, Matura S, Reif A, Rethelyi J, Richarte V, Rommelse N, Siegl A, Ramos-Quiroga JA. Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. Trials. 21: 161. PMID 32046750 DOI: 10.1186/S13063-019-4040-X  0.354
2020 Bugarski-Kirola D, Nunez R, Odetalla R, Bari MA, Bitter I, Feldman PD, (Cathy) Liu I, Stankovic S. T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT Schizophrenia Bulletin. 46: S247-S247. DOI: 10.1093/Schbul/Sbaa029.601  0.367
2019 Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 31255396 DOI: 10.1016/J.Euroneuro.2019.06.008  0.432
2019 Mucci A, Vignapiano A, Bitter I, Austin SF, Delouche C, Dollfus S, Erfurth A, Fleischhacker WW, Giordano GM, Gladyshev I, Glenthøj B, Gütter K, Hofer A, Hubeňák J, Kaiser S, et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 31255394 DOI: 10.1016/J.Euroneuro.2019.05.006  0.407
2019 Bitter I, Mohr P, Balogh L, Látalová K, Kakuszi B, Stopková P, Zmeškalová-Jelenová D, Pulay A, Czobor P. ADHD: a hidden comorbidity in adult psychiatric patients. Attention Deficit and Hyperactivity Disorders. 11: 83-89. PMID 30927233 DOI: 10.1007/S12402-019-00285-9  0.451
2019 Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, Delsol C, Barthe L, Brunner V, Fabre C, Fagard M, Montagne A, Tonner F. Randomized, double-blind, placebo-controlled study of F17464, a preferential D antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30822774 DOI: 10.1038/S41386-019-0355-2  0.35
2019 Vokó Z, Bitter I, Merisch B, Réthelyi J, Molnar A, Pitter J, Gotze A, Ruzsa V, Koczian K, Fonticoli L, Lelli F, Nemeth B. PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE Value in Health. 22: S814-S815. DOI: 10.1016/J.Jval.2019.09.2203  0.353
2018 Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas Brugué M, Bobes J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry : the Journal of the Association of European Psychiatrists. 56: 14-34. PMID 30453134 DOI: 10.1016/J.Eurpsy.2018.11.001  0.437
2018 Stein DJ, Khoo JP, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C, Bauer M, Bitter I, Mosolov SN, Olivier V, Matharan S, Picarel-Blanchot F, de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 28: 970-979. PMID 30135032 DOI: 10.1016/J.Euroneuro.2018.05.006  0.343
2018 Kakuszi B, Bitter I, Czobor P. Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. Comprehensive Psychiatry. 85: 23-29. PMID 29957374 DOI: 10.1016/J.Comppsych.2018.06.003  0.363
2018 Baradits M, Kakuszi B, Bálint S, Fullajtár M, Mód L, Bitter I, Czobor P. Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. European Archives of Psychiatry and Clinical Neuroscience. PMID 29569047 DOI: 10.1007/S00406-018-0889-Z  0.325
2018 Tombor L, Kakuszi B, Papp S, Réthelyi J, Bitter I, Czobor P. Decreased resting gamma activity in adult Attention Deficit/Hyperactivity Disorder. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-33. PMID 29457912 DOI: 10.1080/15622975.2018.1441547  0.388
2018 Németh B, Fasseeh A, Molnár A, Bitter I, Horváth M, Kóczián K, Götze Á, Nagy B. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research. 1-9. PMID 29347854 DOI: 10.1080/14737167.2018.1430571  0.323
2018 Hegerl U, Mergl R, Sander C, Dietzel J, Bitter I, Demyttenaere K, Gusmão R, Arrillaga AG, Zorrilla I, Alocén AG, Sola VP, Vieta E, Juckel G, Zimmermann US, Bauer M, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 28: 185-194. PMID 29174864 DOI: 10.1016/J.Euroneuro.2017.11.003  0.395
2017 Balogh L, Kakuszi B, Papp S, Tombor L, Bitter I, Czobor P. Neural Correlates of Error Monitoring in Adult Attention Deficit Hyperactivity Disorder After Failed Inhibition in an Emotional Go/No-Go Task. The Journal of Neuropsychiatry and Clinical Neurosciences. appineuropsych161001. PMID 28464703 DOI: 10.1176/Appi.Neuropsych.16100183  0.381
2017 Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. Potential role of patients' CYP3A-status in clozapine pharmacokinetics. The International Journal of Neuropsychopharmacology. PMID 28340122 DOI: 10.1093/Ijnp/Pyx019  0.321
2017 Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England). PMID 28185672 DOI: 10.1016/S0140-6736(17)30060-0  0.428
2017 Bitter I, Groc M, Delsol C, Fabre C, Fagard M, Barthe L, Gaudoux F, Brunner V, Brackman F, Tonner F. Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia European Psychiatry. 41: S387-S387. DOI: 10.1016/J.Eurpsy.2017.02.428  0.307
2016 Czobor P, Kakuszi B, Németh K, Balogh L, Papp S, Tombor L, Bitter I. Electrophysiological indices of aberrant error-processing in adults with ADHD: a new region of interest. Brain Imaging and Behavior. PMID 27752922 DOI: 10.1007/S11682-016-9610-X  0.343
2016 Kakuszi B, Tombor L, Papp S, Bitter I, Czobor P. Altered response-preparation in patients with adult ADHD: A high-density ERP study. Psychiatry Research. 249: 57-66. PMID 27000308 DOI: 10.1016/J.Pscychresns.2016.02.008  0.395
2016 Marder S, Laszlovszky I, Szalai E, Szatmári B, Harsányi J, Barabássy A, Debelle M, Durgam S, Bitter I, Németh G. Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31595-4  0.391
2016 Baradits M, Bálint S, Kakuszi B, Bitter I, Czobor P. Gamma band activity in spontaneous EEG in patients with schizophrenia European Neuropsychopharmacology. 26: S344-S345. DOI: 10.1016/S0924-977X(16)31271-8  0.311
2016 Balint S, Baradits M, Kakuszi B, Bitter I, Czobor P. Relationship between cognitive flexibility and symptom presentation in adult ADHD European Neuropsychopharmacology. 26: S344. DOI: 10.1016/S0924-977X(16)31270-6  0.396
2016 Németh G, Debelle M, Laszlovszky I, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Durgam S, Bitter I, Galderisi S. Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial European Psychiatry. 33: s256-s257. DOI: 10.1016/J.Eurpsy.2016.01.652  0.4
2016 Pulay AJ, Bitter I, Papp S, Gulácsi L, Péntek M, Brodszky V, Hevér NV, Rencz F, Baji P. Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD) Applied Research in Quality of Life. 1-16. DOI: 10.1007/S11482-016-9467-6  0.376
2015 Bitter I, Fehér L, Tényi T, Czobor P. Treatment adherence and insight in schizophrenia Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 30: 18-26. PMID 25867885  0.304
2014 Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophrenia Research. 152: 246-54. PMID 24275583 DOI: 10.1016/J.Schres.2013.10.034  0.372
2014 Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietiläinen OP, Lin K, Papiol S, Huttenlocher J, Sigurdsson E, Vassos E, Giegling I, Breuer R, Fraser G, ... ... Bitter I, et al. Common variant at 16p11.2 conferring risk of psychosis. Molecular Psychiatry. 19: 108-14. PMID 23164818 DOI: 10.1038/Mp.2012.157  0.345
2014 Bitter I. EPA-1434 - Antipsychotics European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78634-1  0.31
2014 Bitter I, Czobor P. EPA-1421 – Progress in the selection and delivery of pharmacological treatments in psychiatry European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78623-7  0.303
2014 Czobor P, Kakuszi B, Tombor L, Papp S, Balogh L, Bitter I. EPA-0649 – Response inhibition in attention deficit hyperactivity disorder (ADHD): the influence of emotional-valence on the P300 brain potential European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78021-6  0.387
2014 Kakuszi B, Papp S, Tombor L, Balogh L, Bitter I, Czobor P. EPA-0645 – Neural correlates of impairments in conflict monitoring in ADHD: an event related potential (ERP) study European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78019-8  0.41
2013 Komlósi S, Csukly G, Stefanics G, Czigler I, Bitter I, Czobor P. Fearful face recognition in schizophrenia: An electrophysiological study Schizophrenia Research. 149: 135-140. PMID 23870809 DOI: 10.1016/J.Schres.2013.06.044  0.313
2013 Szuromi B, Bitter I, Czobor P. Functional impairment in adults positively screened for attention-deficit hyperactivity disorder: The role of symptom presentation and executive functioning Comprehensive Psychiatry. 54: 974-981. PMID 23684546 DOI: 10.1016/J.Comppsych.2013.04.002  0.461
2013 Réthelyi JM, Benkovits J, Bitter I. Genes and environments in schizophrenia: The different pieces of a manifold puzzle Neuroscience and Biobehavioral Reviews. 37: 2424-2437. PMID 23628741 DOI: 10.1016/J.Neubiorev.2013.04.010  0.319
2013 Bitter I, Katona L, Zámbori J, Takács P, Fehér L, Diels J, Bacskai M, Lang Z, Gyáni G, Czobor P. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1383-90. PMID 23477752 DOI: 10.1016/J.Euroneuro.2013.02.003  0.303
2013 Kluge M, Hegerl U, Sander C, Dietzel J, Mergl R, Bitter I, Demyttenaere K, Gusmão R, Gonzalez-Pinto A, Perez-Sola V, Vieta E, Juckel G, Zimmermann US, Bauer M, Sienaert P, et al. Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate Bmc Psychiatry. 13. PMID 23446109 DOI: 10.1186/1471-244X-13-71  0.347
2013 Czobor P, Volavka J, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW. Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology. 33: 258-61. PMID 23422388 DOI: 10.1097/Jcp.0B013E3182856886  0.345
2013 Simon V, Czobor P, Bitter I. Is ADHD severity in adults associated with the lifetime prevalence of comorbid depressive episodes and anxiety disorders? European Psychiatry. 28: 308-314. PMID 22986127 DOI: 10.1016/J.Eurpsy.2012.05.002  0.752
2013 Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 196-204. PMID 22647933 DOI: 10.1016/J.Euroneuro.2012.04.019  0.427
2012 Bitter I, Kurimay T. State of psychiatry in Hungary International Review of Psychiatry. 24: 307-313. PMID 22950769 DOI: 10.3109/09540261.2012.694856  0.304
2012 Bitter I, Angyalosi A, Czobor P. Pharmacological treatment of adult ADHD Current Opinion in Psychiatry. 25: 529-534. PMID 22801362 DOI: 10.1097/Yco.0B013E328356F87F  0.43
2012 Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA, Djurovic S, Morken G, Grigoroiu-Serbanescu M, Diaconu CC, Czerski PM, Hauser J, Babadjanova G, Abramova LI, Mühleisen TW, ... ... Bitter I, et al. Replication study and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder. Biological Psychiatry. 72: 645-50. PMID 22560537 DOI: 10.1016/J.Biopsych.2012.02.040  0.337
2012 Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry : the Journal of the Association of European Psychiatrists. 27: 114-28. PMID 22119161 DOI: 10.1016/J.Eurpsy.2011.08.002  0.317
2012 Réthelyi JM, Czobor P, Polgár P, Mersich B, Bálint S, Jekkel E, Magyar K, Mészáros A, Fábián A, Bitter I. General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 262: 107-15. PMID 21792534 DOI: 10.1007/S00406-011-0224-4  0.365
2012 Komlósi S, Csukly G, Stefanics G, Czigler I, Czobor P, Bitter I. AS19-02 - Electrophysiological correlates of impaired facial emotion recognition European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74005-1  0.333
2012 Péntek M, Gulácsi L, V. Hevér N, Papp S, Baji P, Brodszky V, Pulay A, Balogh O, Bitter I. PMH35 EQ-5D Utilities and Productivity of Adults With Attention-Deficit/Hyperactivity Disorder: Review of the Literature and a Cross-Sectional Survey in Hungary Value in Health. 15: A340. DOI: 10.1016/J.Jval.2012.08.825  0.358
2011 Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). The Journal of Clinical Psychiatry. 72: 955-61. PMID 21824456 DOI: 10.4088/Jcp.10M06529  0.39
2011 Szuromi B, Czobor P, Komlósi S, Bitter I. P300 deficits in adults with attention deficit hyperactivity disorder: A meta-analysis Psychological Medicine. 41: 1529-1538. PMID 20961477 DOI: 10.1017/S0033291710001996  0.398
2011 Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OP, ... ... Bitter I, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Molecular Psychiatry. 16: 59-66. PMID 20048749 DOI: 10.1038/Mp.2009.149  0.376
2011 Bitter I. The assessment of self experiences in patients with primary negative symptoms European Psychiatry. 26: 2071-2071. DOI: 10.1016/S0924-9338(11)73774-9  0.401
2011 Benkovits J, Polgár P, Fábián Á, Czobor P, Bitter I, Réthelyi J. The effect of DTNBP1 and comt risk variants and comorbid drug-abuse in patients with schizophrenia: A Gene-Environment Interaction? European Psychiatry. 26: 1345-1345. DOI: 10.1016/S0924-9338(11)73050-4  0.351
2011 Réthelyi J, Polgár P, Benkovits J, Jekkel É, Czobor P, Bitter I. The association of NRG1, DTNBP1, RGS4, G72/G30 and PIP5K2A candidate genes with cognition in patients with schizophrenia and healthy controls European Psychiatry. 26: 811-811. DOI: 10.1016/S0924-9338(11)72516-0  0.355
2011 Farkas K, Réthelyi J, Polgár P, Benkovits J, Fábián Á, Czobor P, Bitter I. BDNF and DISC1 are associated with cognitive dysfunction but not with schizophrenia in a hungarian sample European Psychiatry. 26: 805-805. DOI: 10.1016/S0924-9338(11)72510-X  0.387
2011 Stein D, Ahokas A, Allgulander C, Soegaard J, Bitter I, Lehtmets A, Wahlstedt K, Van Amerigen M. Long-term treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months European Psychiatry. 26: 181-181. DOI: 10.1016/S0924-9338(11)71892-2  0.36
2010 Inczédy-Farkas G, Benkovits J, Balogh N, Almos P, Scholtz B, Zahuczky G, Török Z, Nagy K, Réthelyi J, Makkos Z, Kassai-Farkas A, Egerházy A, Tuzko J, Janka Z, Bitter I, et al. [SCHIZOBANK - The Hungarian national schizophrenia biobank and its role in schizophrenia research and in personalized medicine]. Orvosi Hetilap. 151: 1403-8. PMID 20719713 DOI: 10.1556/Oh.2010.28943  0.362
2010 Polgár P, Réthelyi JM, Bálint S, Komlósi S, Czobor P, Bitter I. Executive function in deficit schizophrenia: What do the dimensions of the Wisconsin Card Sorting Test tell us? Schizophrenia Research. 122: 85-93. PMID 20627227 DOI: 10.1016/J.Schres.2010.06.007  0.41
2010 Réthelyi JM, Bakker SC, Polgár P, Czobor P, Strengman E, Pásztor PI, Kahn RS, Bitter I. Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 792-801. PMID 19937977 DOI: 10.1002/Ajmg.B.31049  0.399
2010 Bitter I, Simon V, Bálint S, Mészáros A, Czobor P. How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample European Archives of Psychiatry and Clinical Neuroscience. 260: 287-296. PMID 19806424 DOI: 10.1007/S00406-009-0076-3  0.742
2010 Szuromi B, Czorbor P, Komlósi S, Bitter I. Meta-analysis of target-related P300 characteristics in adults with attention-deficit/hyperactivity disorder (ADHD): Relevance of target probability International Journal of Psychophysiology. 77: 248-249. DOI: 10.1016/J.Ijpsycho.2010.06.057  0.396
2009 Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): A meta-analysis International Journal of Neuropsychopharmacology. 12: 1137-1147. PMID 19580697 DOI: 10.1017/S1461145709990198  0.736
2009 Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, ... ... Bitter I, et al. Common variants conferring risk of schizophrenia. Nature. 460: 744-7. PMID 19571808 DOI: 10.1038/Nature08186  0.35
2009 Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis British Journal of Psychiatry. 194: 204-211. PMID 19252145 DOI: 10.1192/Bjp.Bp.107.048827  0.736
2009 Bálint S, Czobor P, Komlósi S, Mészáros A, Simon V, Bitter I. Attention deficit hyperactivity disorder (ADHD): Gender- and age-related differences in neurocognition Psychological Medicine. 39: 1337-1345. PMID 18713489 DOI: 10.1017/S0033291708004236  0.743
2009 Polgar P, Bitter I, Keri S, Czobor P. P.3.a.022 Executive function in deficit schizophrenia European Neuropsychopharmacology. 19: S492-S493. DOI: 10.1016/S0924-977X(09)70777-1  0.368
2009 Bitter I. What will be the Consequences from the Changes in ICD-11/DSM-V for Decision Making in Clinical Psychopharmacotherapy? European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)70329-3  0.347
2008 Bálint S, Czobor P, Mészáros A, Simon V, Bitter I. Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review | A felnottkori figyelemhiányos/hiperaktivitás-zavarban tapasztalható neuropszichológial deficit: irodalmi áttekintés Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 23: 324-335. PMID 19129549  0.74
2008 Baran B, Bitter I, Ungvari GS, Nagy Z, Gazdag G. The beginnings of modern psychiatric treatment in Europe. Lessons from an early account of convulsive therapy. European Archives of Psychiatry and Clinical Neuroscience. 258: 434-40. PMID 18504632 DOI: 10.1007/S00406-008-0816-9  0.303
2008 Farkas M, Polgár P, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. Associative learning in deficit and nondeficit schizophrenia. Neuroreport. 19: 55-8. PMID 18281892 DOI: 10.1097/Wnr.0B013E3282F2Dff6  0.75
2008 Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study European Neuropsychopharmacology. 18: 170-180. PMID 17884390 DOI: 10.1016/J.Euroneuro.2007.08.001  0.738
2008 Polgár P, Farkas M, Nagy O, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophrenia Research. 99: 200-7. PMID 17693060 DOI: 10.1016/J.Schres.2007.06.027  0.746
2008 Czobor P, Komlosi S, Bitter I. Placebo-controlled clinical trials of new atypical antipsychotics in schizophrenia European Psychiatry. 23: S157. DOI: 10.1016/J.Eurpsy.2008.01.925  0.335
2007 Polgár P, Farkas M, Nagy O, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. [Learning cognitive skills in depression: the effect of context-change]. Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 271-5. PMID 18167422  0.734
2007 Mészáros A, Czobor P, Bálint S, Simon V, Bitter I. Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review | A felnottkori figyelemhiányos/hiperaktivitás zavar (ADHD) gyógyszeres kezelésének hatékonysága: irodalmi áttekintés Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 259-270. PMID 18167421  0.737
2007 Pethõ B, Tusnády G, Vargha A, Tolna J, Farkas M, Vizkeleti G, Tóth A, Szilágyi A, Bitter I, Kelemen A, Czobor P. Validity of reliability: comparison of interrater reliabilities of psychopathological symptoms. The Journal of Nervous and Mental Disease. 195: 606-13. PMID 17632252 DOI: 10.1097/Nmd.0B013E318093F45D  0.735
2007 Simon V, Czobor P, Bálint S, Mészáros A, Murai Z, Bitter I. Detailed review of epidemiologic studies on adult Attention Deficit/Hyperactivity Disorder (ADHD) | A felnôttkori Figyelemhiányos/Hiperaktivitási Zavar (Attention Deficit/Hyperactivity Disorder--ADHD) epidemiológiai vizsgálatainak részletes áttekintése Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 4-19. PMID 17558040  0.726
2007 Kelemen O, Nagy O, Mátyássy A, Bitter I, Benedek G, Vidnyánszky Z, Kéri S. How well do patients with schizophrenia track multiple moving targets? Neuropsychology. 21: 319-25. PMID 17484595 DOI: 10.1037/0894-4105.21.3.319  0.347
2007 Meszaros A, Bitter I. The assessment of adherence using a questionnaire in patients suffering from schizophrenia European Psychiatry. 22: S104. DOI: 10.1016/J.Eurpsy.2007.01.328  0.354
2006 Treuer T, Anders M, Bitter I, Dobre G, Pecenak J, Dyachkova Y, Harrison G, O'Mahoney J. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). International Journal of Psychiatry in Clinical Practice. 10: 78-90. PMID 24940957 DOI: 10.1080/13651500500409663  0.406
2006 Jones RM, Thompson C, Bitter I. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. European Psychiatry : the Journal of the Association of European Psychiatrists. 21: 1-9. PMID 16487905 DOI: 10.1016/J.Eurpsy.2005.02.002  0.327
2005 Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: A prospective naturalistic study (IC-SOHO) European Psychiatry. 20: 403-408. PMID 16084068 DOI: 10.1016/J.Eurpsy.2005.01.009  0.372
2005 Bitter I, Basson BR, Dossenbach MR. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients International Clinical Psychopharmacology. 20: 19-21. PMID 15602111 DOI: 10.1097/00004850-200501000-00004  0.318
2004 Maciulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Dossenbach M, Walker D. Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. Current Therapeutic Research, Clinical and Experimental. 65: 57-69. PMID 24936104 DOI: 10.1016/S0011-393X(04)90005-7  0.374
2004 Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 457-70. PMID 15589385 DOI: 10.1016/J.Euroneuro.2004.01.002  0.316
2004 Dossenbach M, Erol A, Kessaci MEM, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol Journal of Clinical Psychiatry. 65: 312-321. PMID 15096069 DOI: 10.4088/Jcp.V65N0305  0.425
2004 Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28: 173-80. PMID 14687871 DOI: 10.1016/J.Pnpbp.2003.09.033  0.398
2003 Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 48: 716-21. PMID 14733451 DOI: 10.1177/070674370304801102  0.328
2003 Balázs J, Lecrubier Y, Csiszér N, Koszták J, Bitter I. Prevalence and comorbidity of affective disorders in persons making suicide attempts in Hungary: Importance of the first depressive episodes and of bipolar II diagnoses Journal of Affective Disorders. 76: 113-119. PMID 12943940 DOI: 10.1016/S0165-0327(02)00084-8  0.315
2003 Kasper S, Lowry A, Hodge A, Bitter I, Dossenbach M. P.2.067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophrenia European Neuropsychopharmacology. 13: S308. DOI: 10.1016/S0924-977X(03)92020-7  0.331
2003 Pečeňák J, Kaps P, Treuer T, Bitter I, Hodge A, Grigoriu A, Trzebiatowska I, Herman E, Peciukaitiene D, Smulevich S, Kökényes M. P.2.066 Effectiveness of antipsychotic treatments for patients from the Central Eastern Europe (CEE) region participating in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study: 6-month results European Neuropsychopharmacology. 13: S307-S308. DOI: 10.1016/S0924-977X(03)92019-0  0.325
2003 Bitter I, Maciulis V, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Walker D, Dossenbach M. Safety and efficacy of olanzapine in treating patients with schizophrenia Schizophrenia Research. 60: 273-274. DOI: 10.1016/S0920-9964(03)80432-2  0.339
2000 Balázs J, Bitter I, Lecrubier Y, Csiszér N, Ostorharics G. Prevalence of subthreshold forms of psychiatric disorders in persons making suicide attempts in Hungary. European Psychiatry : the Journal of the Association of European Psychiatrists. 15: 354-61. PMID 11004730 DOI: 10.1016/S0924-9338(00)00503-4  0.313
1999 Bitter I, Brook S, Dossenbach M, Janka Z, Banki C, Selemani S, Grundy S, Martenyi F. Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia European Neuropsychopharmacology. 9: 288. DOI: 10.1016/S0924-977X(99)80346-0  0.362
1992 Bitter I, Scheurer J, Volavka J. Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity???? Reply Journal of Clinical Psychopharmacology. 12: 65. DOI: 10.1097/00004714-199202000-00020  0.343
1992 Bitter I, Scheurer J, Volavka J. Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity?—Reply Current Opinion in Cardiology. 7: 65. DOI: 10.1097/00001573-199202000-00022  0.343
1991 Czobor P, Bitter I, Volavka J. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Research. 36: 129-39. PMID 2017528 DOI: 10.1016/0165-1781(91)90125-9  0.309
1990 Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Comprehensive Psychiatry. 31: 216-26. PMID 2340716 DOI: 10.1016/0010-440X(90)90005-D  0.393
1989 Bitter I, Jaeger J, Volavka J, Cooper T. Failure of subjective complaints to respond to haloperidol in acute schizophrenia Schizophrenia Research. 2: 195. DOI: 10.1016/0920-9964(89)90231-4  0.314
Low-probability matches (unlikely to be authored by this person)
2019 Takács P, Czobor P, Fehér L, Gimesi-Országh J, Fadgyas-Freyler P, Bacskai M, Rakonczai P, Borsi A, Hegyi R, Németh T, Sermon J, Bitter I. Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary. Plos One. 14: e0218071. PMID 31194778 DOI: 10.1371/Journal.Pone.0218071  0.3
2011 Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St. Clair D, Corvin A, Gurling H, ... ... Bitter I, et al. Genome-wide association study identifies five new schizophrenia loci Nature Genetics. 43: 969-978. PMID 21926974 DOI: 10.1038/Ng.940  0.299
2011 Bitter I, Filipovits D, Czobor P. Adverse reactions to duloxetine in depression Expert Opinion On Drug Safety. 10: 839-850. PMID 21545241 DOI: 10.1517/14740338.2011.582037  0.297
2017 Bitter I, Czobor P, Borsi A, Fehér L, Nagy BZ, Bacskai M, Rakonczai P, Hegyi R, Németh T, Varga P, Gimesi-Országh J, Fadgyas-Freyler P, Sermon J, Takács P. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. European Psychiatry : the Journal of the Association of European Psychiatrists. 45: 97-103. PMID 28753464 DOI: 10.1016/J.Eurpsy.2017.05.022  0.297
2022 Czobor P, Kakuszi B, Bitter I. Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. Schizophrenia Bulletin. PMID 35713342 DOI: 10.1093/schbul/sbac061  0.296
2004 Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ, Akiskal H, Allain H, Ayuso-Gutiérrez J, Baldwin D, Bech P, Benkert O, Berk M, Bitter I, Bourgeois M, Burrows G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment World Journal of Biological Psychiatry. 5: 120-135. PMID 15346536 DOI: 10.1080/15622970410029924  0.296
2020 Vokó Z, Bitter I, Mersich B, Réthelyi J, Molnár A, Pitter JG, Götze Á, Horváth M, Kóczián K, Fonticoli L, Lelli F, Németh B. Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling-an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine. Cost Effectiveness and Resource Allocation : C/E. 18: 28. PMID 32874137 DOI: 10.1186/S12962-020-00224-W  0.294
2011 Steinberg S, de Jong S, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OP, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, ... ... Bitter I, et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Human Molecular Genetics. 20: 4076-81. PMID 21791550 DOI: 10.1093/Hmg/Ddr325  0.292
2009 Czobor P, Bitter I. How to Interpret Efficacy and Safety Data of Antidepressive Drugs and Placebo Response Rates? European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)70312-8  0.291
2006 Treuer T, Anders M, Bitter I, Dobre G, Pecenak J, Dyachkova Y, Harrison G, O'Mahoney J. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: Results after 1 year from a prospective, observational study (IC-SOHO) International Journal of Psychiatry in Clinical Practice. 10: 78-90. DOI: 10.1080/13651500500409663  0.291
2015 Bálint S, Bitter I, Czobor P. Neurobiological correlates of cognitive flexibility in ADHD - A systematic review of the literature | A kognitív rugalmasság neurobiológiai korrelátumainak vizsgálata ADHD-ban lrodalmi áttekintés Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 30: 363-371. PMID 26771696  0.288
2022 Bitter I, Mohr P, Raspopova N, Szulc A, Samochowiec J, Micluia IV, Skugarevsky O, Herold R, Mihaljevic-Peles A, Okribelashvili N, Dragašek J, Adomaitiene V, Rancans E, Chihai J, Maruta N, et al. Assessment and Treatment of Negative Symptoms in Schizophrenia-A Regional Perspective. Frontiers in Psychiatry. 12: 820801. PMID 35185643 DOI: 10.3389/fpsyt.2021.820801  0.288
1981 Pethö B, Gráf L, Karczag I, Bitter I, Tolna J, Baraczka K, Li CH. beta-Endorphin and schizophrenia. Lancet (London, England). 1: 212-3. PMID 6109874 DOI: 10.1016/S0140-6736(81)90080-5  0.286
1987 Kopp MS, Mihály K, Linka E, Bitter I. Electrodermally differentiated subgroups of anxiety patients. I. Automatic and vigilance characteristics. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 5: 43-51. PMID 3597169 DOI: 10.1016/0167-8760(87)90071-7  0.282
2007 Švestka J, Bitter I. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders Neuroendocrinology Letters. 28: 95-116. PMID 17262005  0.28
2014 Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW, Walker-Tilley TR, Bitter I, Brown VJ, Buitelaar J, Ciccocioppo R, Cools R, Escera C, Fleischhacker W, Flor H, et al. Stratified medicine for mental disorders. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 5-50. PMID 24176673 DOI: 10.1016/J.Euroneuro.2013.09.010  0.279
2016 Kakuszi B, Tombor L, Papp S, Bitter I, Czobor P. Altered response-preparation in patients with adult ADHD: A high-density ERP study Psychiatry Research - Neuroimaging. 249: 57-66. DOI: 10.1016/j.pscychresns.2016.02.008  0.279
2003 Potkin SG, Alphs L, Hsu C, Krishnan KRR, Anand R, Young FK, Meltzer H, Green A, Altinsan S, Altman S, Avigo L, Balon R, Benešová V, Bengochea L, Bitter I, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial Biological Psychiatry. 54: 444-452. DOI: 10.1016/S0006-3223(03)00178-1  0.278
2021 Tombor L, Kakuszi B, Papp S, Réthelyi J, Bitter I, Czobor P. Atypical resting-state gamma band trajectory in adult attention deficit/hyperactivity disorder. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 34164742 DOI: 10.1007/s00702-021-02368-2  0.276
2004 MacIulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Dossenbach M, Walker D. Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study Current Therapeutic Research - Clinical and Experimental. 65: 57-69. DOI: 10.1016/S0011-393X(04)90005-7  0.275
2019 Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, ... ... Bitter I, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Jama Psychiatry. PMID 31166571 DOI: 10.1001/Jamapsychiatry.2019.1189  0.275
1992 Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou JC, Crowner M. Haloperidol blood levels and clinical effects. Archives of General Psychiatry. 49: 354-61. PMID 1586270 DOI: 10.1001/Archpsyc.1992.01820050018002  0.272
2006 Füredi J, Mohr P, Swingler D, Bitter I, Gheorghe MD, Hotujac L, Jarema M, Kocmur M, Koychev GI, Mosolov SN, Pecenak J, Rybakowski J, Svestka J, Sartorius N. Psychiatry in selected countries of Central and Eastern Europe: An overview of the current situation Acta Psychiatrica Scandinavica. 114: 223-231. PMID 16968359 DOI: 10.1111/J.1600-0447.2006.00804.X  0.272
2000 Balázs J, Bitter I, Lecrubier Y, Csiszér N, Koszták J. Prevalence of mental disorders and their subthreshold forms in suicide attempters in Hungary European Neuropsychopharmacology. 10: 393. DOI: 10.1016/S0924-977X(00)80550-7  0.268
2005 Gazdag G, Bitter I, Ungvári G, Gerevich J. Atropine coma: A historical note Journal of Ect. 21: 203-206. PMID 16301877 DOI: 10.1097/01.Yct.0000180041.13962.E4  0.267
1991 BITTER I, VOLAVKA J, SCHEURER J. The Concept of the Neuroleptic Threshold Journal of Clinical Psychopharmacology. 11: 28???33. DOI: 10.1097/00004714-199102000-00004  0.266
2010 Bitter I, Treuer T, Dilbaz N, Oyffe I, Ciorabai EM, Gonzalez SL, Ruschel S, Salburg J, Dyachkova Y. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study World Journal of Biological Psychiatry. 11: 894-903. PMID 20653494 DOI: 10.3109/15622975.2010.505663  0.265
2017 Stein DJ, Khoo JP, Ameringen DMV, Hoschl C, Ahokas A, Bauer M, Bitter I, Jarema M, Mosolov S, Vavrusova L, Picarel-Blanchot F, Matharan S, Olivier V. Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder European Neuropsychopharmacology. 27. DOI: 10.1016/S0924-977X(17)31762-5  0.26
2010 Bitter I. S26-03 - Off label use of drugs in psychiatry European Psychiatry. 25: 10. DOI: 10.1016/S0924-9338(10)70010-9  0.259
2024 Schnorr I, Siegl A, Luckhardt S, Wenz S, Friedrichsen H, El Jomaa H, Steinmann A, Kilencz T, Arteaga-Henríquez G, Ramos-Sayalero C, Ibanez-Jimenez P, Rosales-Ortiz SK, Bitter I, Fadeuilhe C, Ferrer M, et al. Inflammatory biotype of ADHD is linked to chronic stress: a data-driven analysis of the inflammatory proteome. Translational Psychiatry. 14: 37. PMID 38238292 DOI: 10.1038/s41398-023-02729-3  0.258
2012 Gazdag G, Tolna J, Bitter I. [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature]. Neuropsychopharmacologia Hungarica : a Magyar PszichofarmakolóGiai EgyesüLet Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 14: 189-95. PMID 22987732  0.255
2019 Kiss Á, Menus Á, Tóth K, Déri M, Sirok D, Gabri E, Belic A, Csukly G, Bitter I, Monostory K. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European Archives of Psychiatry and Clinical Neuroscience. PMID 30604050 DOI: 10.1007/S00406-018-0975-2  0.255
2019 Daly EJ, Trivedi M, Janik A, Li H, Zhang Y, Li X, Lane R, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, ... Bitter I, et al. Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (sustain-1) European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2018.11.1076  0.254
2002 Detke M, Bitter I, Lu Y, Goldstein D, Demitrack M. Duloxetine 60 mg QD is efficacious in the treatment of depression European Psychiatry. 17: 98. DOI: 10.1016/S0924-9338(02)80445-X  0.251
2016 Baumann P, Spies M, Möller HJ, Kasper S, Bitter I, Laux G. A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-26. PMID 26850137 DOI: 10.3109/15622975.2016.1149219  0.249
2015 Fodor KE, Bitter I. [Psychological interventions following trauma to prevent posttraumatic stress disorder. A systematic review of the literature]. Orvosi Hetilap. 156: 1321-34. PMID 26256496 DOI: 10.1556/650.2015.30231  0.248
2023 Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthøj B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). The Lancet. Psychiatry. PMID 36716759 DOI: 10.1016/S2215-0366(23)00005-6  0.243
2015 Wykes T, Haro JM, Belli SR, Obradors-Tarragó C, Arango C, Ayuso-Mateos JL, Bitter I, Brunn M, Chevreul K, Demotes-Mainard J, Elfeddali I, Evans-Lacko S, Fiorillo A, Forsman AK, Hazo JB, et al. Mental health research priorities for Europe. The Lancet. Psychiatry. PMID 26404415 DOI: 10.1016/S2215-0366(15)00332-6  0.241
1983 Pethö B, Gráf L, Karczag I, Borvendég J, Bitter I, Barna I, Hermann I, Tolna J, Baraczka K. beta-Endorphin administration to acute schizophrenic patients: a double blind study. Annals of the New York Academy of Sciences. 398: 460-9. PMID 6297365 DOI: 10.1111/J.1749-6632.1982.Tb39517.X  0.24
2017 Winkler P, Krupchanka D, Roberts T, Kondratova L, Machů V, Höschl C, Sartorius N, Van Voren R, Aizberg O, Bitter I, Cerga-Pashoja A, Deljkovic A, Fanaj N, Germanavicius A, Hinkov H, et al. A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe. The Lancet. Psychiatry. PMID 28495549 DOI: 10.1016/S2215-0366(17)30135-9  0.236
2009 Gazdag G, Bitter I, Ungvari GS, Baran B, Fink M. László Meduna's pilot studies with camphor inductions of seizures: the first 11 patients. The Journal of Ect. 25: 3-11. PMID 19209069 DOI: 10.1097/Yct.0B013E31819359Fc  0.236
2014 Haro JM, Ayuso-Mateos JL, Bitter I, Demotes-Mainard J, Leboyer M, Lewis SW, Linszen D, Maj M, McDaid D, Meyer-Lindenberg A, Robbins TW, Schumann G, Thornicroft G, Van Der Feltz-Cornelis C, Van Os J, et al. ROAMER: roadmap for mental health research in Europe. International Journal of Methods in Psychiatric Research. 23: 1-14. PMID 24375532 DOI: 10.1002/Mpr.1406  0.234
2000 Balázs J, Bitter I, Lecrubier Y, Csiszér N, Koszták J. P01.168 First major depressive episode among suicide attempters in Hungary European Psychiatry. 15: 365s-365s. DOI: 10.1016/S0924-9338(00)94575-9  0.234
2023 Bitter I, Czobor P, Kakuszi B, Réthelyi J. [Psychiatric disorders are associated with high mortality rates: somatic comorbidity and mortality in autism spectrum disorder and schizophrenia]. Orvosi Hetilap. 164: 1287-1293. PMID 37598366 DOI: 10.1556/650.2023.32843  0.233
2008 Baran B, Bitter I, Fink M, Gazdag G, Shorter E. Károly Schaffer and his school: the birth of biological psychiatry in Hungary, 1890-1940. European Psychiatry : the Journal of the Association of European Psychiatrists. 23: 449-56. PMID 18078742 DOI: 10.1016/J.Eurpsy.2007.10.003  0.233
2021 Katona L, Bitter I, Czobor P. A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials? Translational Psychiatry. 11: 510. PMID 34615850 DOI: 10.1038/s41398-021-01636-9  0.227
2009 Gazdag G, Bitter I, Ungvari GS, Baran B. Convulsive therapy turns 75. The British Journal of Psychiatry : the Journal of Mental Science. 194: 387-8. PMID 19407263 DOI: 10.1192/Bjp.Bp.108.062547  0.226
2012 Simon Z, Peragovics A, Vigh-Smeller M, Csukly G, Tombor L, Yang Z, Zahoránszky-Kohalmi G, Végner L, Jelinek B, Hári P, Hetényi C, Bitter I, Czobor P, Málnási-Csizmadia A. Drug effect prediction by polypharmacology-based interaction profiling. Journal of Chemical Information and Modeling. 52: 134-45. PMID 22098080 DOI: 10.1021/Ci2002022  0.221
2006 Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakolã³Giai Egyesã¼Let Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 8: 201-9. PMID 17211055  0.22
2003 Bitter I, Chou JC, Ungvari GS, Tang WK, Xiang Z, Iwanami A, Gaszner P. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry. 36: 143-9. PMID 12905100 DOI: 10.1055/s-2003-41199  0.219
2012 Baran B, Bitter I, Ungvari GS, Gazdag G. The birth of convulsive therapy revisited: a reappraisal of László Meduna's first cohort of patients. Journal of Affective Disorders. 136: 1179-82. PMID 22230354 DOI: 10.1016/J.Jad.2011.11.045  0.216
2022 Dollfus S, Mucci A, Giordano GM, Bitter I, Austin SF, Delouche C, Erfurth A, Fleischhacker WW, Movina L, Glenthøj B, Gütter K, Hofer A, Hubenak J, Kaiser S, Libiger J, et al. European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry. 13: 826465. PMID 35173641 DOI: 10.3389/fpsyt.2022.826465  0.216
2011 Nagy J, Bitter I. [Evaluation of the psychometric properties of the Calgary Depression Scale for Schizophrenics (CDSS) in a Hungarian clinical population of patients with schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar PszichofarmakolóGiai EgyesüLet Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 13: 33-40. PMID 21451190  0.214
2017 Herold R, Szekeres G, Bitter I. Continuous maintenance antipsychotic treatment in schizophrenia. Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata. 32: 296-306. PMID 29135443  0.212
2016 Szkultecka-Dębek M, Miernik K, Stelmachowski J, Jakovljević M, Jukić V, Aadamsoo K, Janno S, Bitter I, Tolna J, Jarema M, Jankovic S, Pecenak J, Vavrusova L, Tavčar R, Walczak J, et al. Treatment patterns of schizophrenia based on the data from seven Central and Eastern European Countries. Psychiatria Danubina. 28: 234-242. PMID 27658832  0.21
2004 Bitter I. Modern pharmacotherapy of schizophrenia | A szkizofrénia modern gyógyszeres kezelése Orvosi Hetilap. 145: 105-109. PMID 15027331  0.209
2007 Gazdag G, Baran B, Bitter I, Ungvári GS, Gerevich J. Regressive and intensive methods of electroconvulsive therapy: a brief historical note. The Journal of Ect. 23: 229-32. PMID 18090693 DOI: 10.1097/Yct.0B013E3181593D75  0.209
2022 Correll CU, Bitter I, Hoti F, Mehtälä J, Wooller A, Pungor K, Tiihonen J. Factors and their weight in reducing life expectancy in schizophrenia. Schizophrenia Research. 250: 67-75. PMID 36368280 DOI: 10.1016/j.schres.2022.10.019  0.208
2004 Bitter I. Treatment of schizophrenia | A szkizofrénia kezelése Orvosi Hetilap. 145: 1281-1283. PMID 15264758  0.207
2010 Simon Z, Vigh-Smeller M, Peragovics A, Csukly G, Zahoránszky-Kohalmi G, Rauscher AA, Jelinek B, Hári P, Bitter I, Málnási-Csizmadia A, Czobor P. Relating the shape of protein binding sites to binding affinity profiles: is there an association? Bmc Structural Biology. 10: 32. PMID 20923553 DOI: 10.1186/1472-6807-10-32  0.205
2016 Szkultecka-Dębek M, Miernik K, Stelmachowski J, Jakovljević M, Jukić V, Aadamsoo K, Janno S, Bitter I, Tolna J, Jarema M, Jankovic S, Pecenak J, Vavrusova L, Tavčar R, Walczak J, et al. Schizophrenia causes significant burden to patients' and caregivers' lives. Psychiatria Danubina. 28: 104-10. PMID 27287783  0.203
1986 Pethö B, Bitter I. Types of complaints in psychiatric and internal medical patients. Psychopathology. 18: 241-53. PMID 3832138 DOI: 10.1159/000284412  0.201
2008 Komlósi S, Czobor P, Bálint S, Bitter I. The relationship between cognition and functional outcome in schizophrenia | A szkizofréniában tapasztalható kognitív deficit osszefüggése a mindennapi funkcióképességgel Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 23: 166-176. PMID 18956623  0.201
2013 Gazdag G, Takács R, Tolna J, Iványi Z, Ungvari GS, Bitter I. Electroconvulsive therapy in a Hungarian academic centre (1999-2010) Psychiatria Danubina. 25: 366-370. PMID 24247048  0.199
2006 Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America Schizophrenia Research. 81: 139-143. PMID 16253478 DOI: 10.1016/j.schres.2005.07.032  0.198
2020 Baradits M, Bálint S, Kakuszi B, Bitter I, Czobor P. Minimum Spanning Tree Measures Show Altered Functional Connectivity of EEG Microstates in Patients With Schizophrenia Biological Psychiatry. 87: S308. DOI: 10.1016/j.biopsych.2020.02.793  0.197
2012 Bitter I, Galderisi S. E.05.01 The unmet needs in the treatment of schizophrenia European Neuropsychopharmacology. 22: S150-S151. DOI: 10.1016/S0924-977X(12)70208-0  0.191
2008 Réthelyi J, Polgár P, Czobor P, Bitter I. Recent advances in the genetics of schizophrenia and the practical implications of the results | A szkizofrénia genetikai hátterére irányuló kutatások ujabb eredményei es ezek alkalmazási lehetoségei. Irodalmi osszefoglalás Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 23: 152-165. PMID 18956622  0.191
2016 Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, Bitter I, Bilanakis N, Schreiner A. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opinion On Pharmacotherapy. 1-11. PMID 27042990 DOI: 10.1080/14656566.2016.1174692  0.189
2022 Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, Smith N, Bitter I, Gorwood P, Taipale H, Tiihonen J. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 21: 248-271. PMID 35524619 DOI: 10.1002/wps.20994  0.189
2024 Solmi M, Croatto G, Fornaro M, Schneider LK, Rohani-Montez SC, Fairley L, Smith N, Bitter I, Gorwood P, Taipale H, Tiihonen J, Cortese S, Dragioti E, Rietz ED, Nielsen RE, et al. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 80: 55-69. PMID 38368796 DOI: 10.1016/j.euroneuro.2023.12.010  0.186
2016 Huerta-Ramos E, Escobar-Villegas MS, Rubinstein K, Unoka ZS, Grasa E, Hospedales M, Jääskeläinen E, Rubio-Abadal E, Caspi A, Bitter I, Berdun J, Seppälä J, Ochoa S, Fazekas K, et al. Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. Jmir Mhealth and Uhealth. 4: e112. PMID 27682896 DOI: 10.2196/mhealth.5716  0.186
2003 Nitz N, Namjoshi M, Dossenbach M, Bitter I, Saylan M. Schizophrenia and psychiatric services use in Turkey among initiators of olanzapine or risperidone Schizophrenia Research. 60: 341. DOI: 10.1016/S0920-9964(03)80339-0  0.185
2022 Kristóf Z, Baranyi M, Tod P, Mut-Arbona P, Demeter K, Bitter I, Sperlágh B. Elevated serum purine levels in schizophrenia: a reverse translational study to identify novel inflammatory biomarkers. The International Journal of Neuropsychopharmacology. PMID 35443035 DOI: 10.1093/ijnp/pyac026  0.181
2012 Réthelyi JM, Polgár P, Benkovits J, Farkas K, Pulay AJ, Czobor P, Bitter I. Poster #102 THE ASSOCIATION OF NRG1, DTNBP1, RGS4, G72/G30, DISCI AND BDNF CANDIDATE GENES WITH COGNITION IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS Schizophrenia Research. 136: S128. DOI: 10.1016/S0920-9964(12)70417-6  0.175
2004 Korb FA, Yenilmez C, Belaid A, Ghazi M, Omar A, Bitter I. The intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study: baseline clinical and functional characteristics and antipsychotic use patterns in the North Africa and Middle Eastern (AMEA) region: original article African Journal of Psychiatry. 7. DOI: 10.4314/AJPSY.V7I3.30170  0.172
2001 Lepine JP, Altamura C, Ansseau M, Gutierrez JL, Bitter I, Lader M, Waintraub L. Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study dagger. Human Psychopharmacology. 16: 219-227. PMID 12404574 DOI: 10.1002/hup.289  0.17
2008 Baran B, Bitter I, Ungvári GS, Nagy Z, Gazdag G. O advento do tratamento psiquiátrico moderno: a terapia convulsiva de László Meduna Revista De Psiquiatria Clinica. 35: 165-169. DOI: 10.1590/S0101-60832008000400007  0.17
2021 Kirkpatrick B, Cohen A, Bitter I, Strauss GP. Primary Negative Symptoms: Refining the Research Target. Schizophrenia Bulletin. PMID 34104967 DOI: 10.1093/schbul/sbab069  0.154
1989 Richardson M, Casey D, Bitter I. Elderly psychiatric patients: Parkinsonism, sex, and MAO relationships Biological Psychiatry. 25: A73. DOI: 10.1016/0006-3223(89)91634-X  0.148
2014 Altamura AC, Barnas C, Bitter I, Fleischhacker W, Gaebel W, Hirsch S, Kissling W, Kufferle B, Moller HJ, Naber D, Pickar D, Pullen I, Tollefson GD. Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. International Journal of Psychiatry in Clinical Practice. S25-30. PMID 24936884 DOI: 10.3109/13651509709024747  0.146
2002 Nitz N, Namjoshi M, Dossenbach M, Bitter I, Janko C, Becker S, Richardson J. Mental health services use among outpatients with schizophrenia in Egypt, Saudi Arabia, Turkey, and Algeria European Neuropsychopharmacology. 12: 305-306. DOI: 10.1016/S0924-977X(02)80447-3  0.14
2006 Ungvári SG, Gazdag G, Bitter I, Gerevich J. The beginnings of modern biological psychiatry in Hungary: the atropine coma. A historical overview | A modern magyar biológiai pszichiátria kezdetei: az atropin kóma. Történeti attekintés Neuropsychopharmacologia Hungarica : a Magyar PszichofarmakolóGiai EgyesüLet Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 8: 79-84. PMID 17073216  0.132
2016 Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. Optimization of clonazepam therapy adjusted to patient's CYP3A-status and NAT2 genotype. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 27639091 DOI: 10.1093/ijnp/pyw083  0.128
2010 Mohr P, Bitter I, Svestka J, Seifritz E, Karamustafalioglu O, Koponen H, Sartorius N. Management of depression in the presence of pain symptoms. Psychiatria Danubina. 22: 4-13. PMID 20305585  0.126
2002 Goldstein D, Bitter I, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack M. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine European Psychiatry. 17: 98. DOI: 10.1016/S0924-9338(02)80446-1  0.124
2008 Baran B, Bitter I, Ungvári GS, Nagy Z, Gazdag G. [The birth of biological therapy in Hungary: the story of László Meduna's first patient receiving convulsive therapy]. Psychiatria Hungarica : a Magyar Pszichiã¡Triai Tã¡Rsasã¡G Tudomã¡Nyos Folyã³Irata. 23: 366-75. PMID 19129553  0.122
2023 Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. The New England Journal of Medicine. 389: 1298-1309. PMID 37792613 DOI: 10.1056/NEJMoa2304145  0.122
2013 Szily E, Bitter I. Designer drugs in psychiatric practice - A review of the literature and the recent situation in hungary | quot;designer" drogok a pszichiátriai gyakorlatban - Irodalmi áttekintés és a magyarországi helyzet elemzése Neuropsychopharmacologia Hungarica. 15: 223-231. PMID 24380963  0.12
1995 Richardson M, Read L, Reilly M, Suckow R, Casey D, Bitter I. Significant interactions: Gender, movement disorders, and biochemical variables Schizophrenia Research. 15: 209. DOI: 10.1016/0920-9964(95)95643-N  0.099
2020 Karvaly G, Bitter I. [Therapeutic drug monitoring of atypical antipsychotics and antidepressants: conclusions of the first year at Semmelweis University]. Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata. 35: 463-470. PMID 33263295  0.097
2019 Bitter I, Bolyós C, Nagy M, Réthelyi J, Czobor P. [How we see the development of clinical trials from the investigators' side?] Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata. 34: 393-402. PMID 31767799  0.096
2009 Stubnya G, Nagy Z, Bagdy G, Rihmer Z, Molnár MJ, Harmatta J, Kovács GG, Perczel Forintos D, Simon L, Bitter I. [The way out from crisis--from the closing of the National Psychiatric and Neurologic Institute (OPNI) to Semmelweis University]. Psychiatria Hungarica : a Magyar Pszichiã¡Triai Tã¡Rsasã¡G Tudomã¡Nyos Folyã³Irata. 24: 193-204. PMID 19794227  0.092
2022 Solmi M, Thompson T, Estradé A, Agorastos A, Radua J, Cortese S, Dragioti E, Leisch F, Vancampfort D, Thygesen LC, Aschauer H, Schloegelhofer M, Aschauer E, Schneeberger A, Huber CG, ... ... Bitter I, et al. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults. Journal of Affective Disorders. PMID 36586617 DOI: 10.1016/j.jad.2022.12.022  0.092
2021 Solmi M, Estradé A, Thompson T, Agorastos A, Radua J, Cortese S, Dragioti E, Leisch F, Vancampfort D, Thygesen LC, Aschauer H, Schloegelhofer M, Akimova E, Schneeberger A, Huber CG, ... ... Bitter I, et al. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. Journal of Affective Disorders. 299: 393-407. PMID 34949568 DOI: 10.1016/j.jad.2021.07.048  0.087
2006 Gazdag G, Bitter I, Gerevich J, Ungvári G. Chapters from the history of biological psychiatry: efforts made to increase the efficacy of electroconvulsive therapy | Fejezetek a biológiai pszichiátria történetébol: az elektrokonvulzív kezelés hatékonyságának fokozására tett kísérletek Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 21: 351-359. PMID 17297197  0.081
2005 Bitter I. Antipsychotic treatment and metabolic syndrome. Consensus meeting of the Metabolic Working Group of the Hungarian Diabetes Society and the Hungarian Psychiatric Collegium | Antipszichotikus terápia és metabolikus szindróma Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata.. 20: 312-315. PMID 16462008  0.072
2010 Stubnya G, Nagy Z, Lammers CH, Rihmer Z, Bitter I. Deinstitutionalization in Europe: two recent examples from Germany and Hungary. Psychiatria Danubina. 22: 406-12. PMID 20856183  0.071
2000 Bitter I. S06.01 Continuing medical (psychiatric) education in Hungary European Psychiatry. 15: 222s-222s. DOI: 10.1016/S0924-9338(00)93950-6  0.07
2010 Mohr P, Bitter I, Constant E, Jakovljević M, Jarema M, Pecenak J, Seifritz E, Švestka J, Sartorius N. Myth and reality of pragmatic trials Psychiatria Danubina. 22: 2-3. PMID 20305584  0.07
2016 Bitter I. The Continuity of Psychiatrical Schools at Hungarian Universities. Orvostorteneti Kozlemenyek. 62: 131-2. PMID 30070458  0.066
2021 Solmi M, Estradé A, Thompson T, Agorastos A, Radua J, Cortese S, Dragioti E, Leisch F, Vancampfort D, Thygesen LC, Aschauer H, Schloegelhofer M, Akimova E, Schneeberger A, Huber CG, ... ... Bitter I, et al. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders. 299: 367-376. PMID 34606810 DOI: 10.1016/j.jad.2021.09.090  0.054
2019 Paudics A, Kubinyi M, Bitter I, Bojtár M. Carboxylato-pillar[6]arene-based fluorescent indicator displacement assays for the recognition of monoamine neurotransmitters. Rsc Advances. 9: 16856-16862. PMID 35516407 DOI: 10.1039/c9ra03241j  0.049
2007 Pál K, Kállay M, Köhler G, Zhang H, Bitter I, Kubinyi M, Vidóczy T, Grabner G. Efficient singlet-state deactivation of cyano-substituted indolines in protic solvents via CN-HO hydrogen bonds Chemphyschem. 8: 2627-2635. PMID 18058777 DOI: 10.1002/cphc.200700479  0.044
2006 Szigeti Z, Malon A, Vigassy T, Csokai V, Grün A, Wygladacz K, Ye N, Xu C, Chebny VJ, Bitter I, Rathore R, Bakker E, Pretsch E. Novel potentiometric and optical silver ion-selective sensors with subnanomolar detection limits. Analytica Chimica Acta. 572: 1-10. PMID 17723454 DOI: 10.1016/J.Aca.2006.05.009  0.042
2017 Bojtár M, Simon A, Bombicz P, Bitter I. Expanding the Pillararene Chemistry: Synthesis and Application of a 10 + 1 Functionalized Pillar[5]arene. Organic Letters. PMID 28825839 DOI: 10.1021/acs.orglett.7b02092  0.041
2018 Szakács Z, Rousseva S, Bojtár M, Hessz D, Bitter I, Kállay M, Hilbers M, Zhang H, Kubinyi M. Experimental evidence of TICT state in 4-piperidinyl-1,8-naphthalimide - a kinetic and mechanistic study. Physical Chemistry Chemical Physics : Pccp. PMID 29589611 DOI: 10.1039/c7cp08555a  0.041
2006 Onel L, Bourceanu G, Bitter I, Wittmann M, Noszticzius Z. Uncatalyzed reactions in the classical Belousov-Zhabotinsky system. 2. The malonic acid-bromate reaction in acidic media. The Journal of Physical Chemistry. A. 110: 990-6. PMID 16419999 DOI: 10.1021/jp055259o  0.04
2007 Kunsagi-Maté S, Szabó K, Desbat B, Bruneel JL, Bitter I, Kollar L. Complexation of phenols by calix[4]arene Diethers in a low-permittivity solvent. Self-switched complexation by 25,27-Dibenzyloxycalix[4]arene. The Journal of Physical Chemistry. B. 111: 7218-23. PMID 17547439 DOI: 10.1021/jp068567a  0.04
2018 Bojtár M, Janzsó-Berend PZ, Mester D, Hessz D, Kállay M, Kubinyi M, Bitter I. An uracil-linked hydroxyflavone probe for the recognition of ATP. Beilstein Journal of Organic Chemistry. 14: 747-755. PMID 29719572 DOI: 10.3762/bjoc.14.63  0.04
2005 Kunsági-Máté S, Szabó K, Bitter I, Nagy G, Kollár L. Unexpected effect of charge density of the aromatic guests on the stability of calix[6]arene-phenol host-guest complexes. The Journal of Physical Chemistry. A. 109: 5237-42. PMID 16833881 DOI: 10.1021/jp050082j  0.039
2002 Kunsági-Máté S, Bitter I, Grün A, Nagy G, Kollár L. Anisotropy decay study on the host-guest interaction of distally dialkylated calix[4]arenes with 1-chloro-4-(trifluoromethyl)benzene Journal of Biochemical and Biophysical Methods. 53: 101-108. PMID 12406591 DOI: 10.1016/S0165-022X(02)00097-0  0.035
2000 Bitter I. W05.01 Mental health care in Hungary European Psychiatry. 15: 311s-311s. DOI: 10.1016/S0924-9338(00)94368-2  0.031
2016 Szakács Z, Bojtár M, Drahos L, Hessz D, Kállay M, Vidóczy T, Bitter I, Kubinyi M. The kinetics and mechanism of photooxygenation of 4'-diethylamino-3-hydroxyflavone. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 15: 219-27. PMID 26738442 DOI: 10.1039/c5pp00358j  0.031
2005 Kubinyi M, Vidóczy T, Varga O, Nagy K, Bitter I. Absorption and fluorescence spectroscopic study on complexation of oxazine 1 dye by calix[8]arenesulfonate Applied Spectroscopy. 59: 134-139. PMID 15720749 DOI: 10.1366/0003702052940477  0.03
2008 Urbanová N, Kádár M, Tóth K, Bogáti B, Andruch V, Bitter I. Fluorescent iminodiacetamide derivatives as potential ionophores for optical zinc ion-selective sensors. Analytical Sciences : the International Journal of the Japan Society For Analytical Chemistry. 24: 727-33. PMID 18544860 DOI: JST.JSTAGE/analsci/24.727  0.03
2004 Kubinyi M, Pál K, Baranyai P, Grofcsik A, Bitter I, Grün A. Absorption, fluorescence, and cd spectroscopic study of chiral recognition by a binaphthyl-derived chromogenic calixcrown host. Chirality. 16: 174-9. PMID 14770414 DOI: 10.1002/chir.20003  0.027
2005 Keglevich G, Forintos H, Ujvari A, Ludanyi K, Bitter I, Toeke L. Generation and Utilization of P-Cyclic α-Methoxycarbonylmethylenephosphoranes. Cheminform. 36. DOI: 10.1002/CHIN.200545104  0.027
2008 Balázs B, Grün A, Bitter I, Tóth G. Studies on inclusion complexes of calix[4]arenes capped by diamide bridges with small organic molecules. Magnetic Resonance in Chemistry : Mrc. 46: 707-12. PMID 18449955 DOI: 10.1002/mrc.2233  0.025
2021 Hessz D, Bádogos S, Bojtár M, Bitter I, Drahos L, Kubinyi M. Complexes of carboxylato pillar[6]arene with Brooker-type merocyanines: Spectral properties, pK shifts and the design of a displacement assay for trimethyl lysine. Spectrochimica Acta. Part a, Molecular and Biomolecular Spectroscopy. 252: 119455. PMID 33515854 DOI: 10.1016/j.saa.2021.119455  0.021
2004 Csokai V, Grün A, Balázs B, Tóth G, Horváth G, Bitter I. Unprecedented cyclizations of calix[4]arenes with glycols under the Mitsunobu protocol, part 2.(1) O,O-and O,S-bridged calixarenes. Organic Letters. 6: 477-80. PMID 14961602 DOI: 10.1021/ol0359315  0.021
2020 Paudics A, Hessz D, Bojtár M, Gyarmati B, Szilágyi A, Kállay M, Bitter I, Kubinyi M. Binding Modes of a Phenylpyridinium Styryl Fluorescent Dye with Cucurbiturils. Molecules (Basel, Switzerland). 25. PMID 33153219 DOI: 10.3390/molecules25215111  0.02
2018 Hessz D, Bojtár M, Mester D, Szakács Z, Bitter I, Kállay M, Kubinyi M. Hydrogen bonding effects on the fluorescence properties of 4'-diethylamino-3-hydroxyflavone in water and water-acetone mixtures. Spectrochimica Acta. Part a, Molecular and Biomolecular Spectroscopy. 203: 96-105. PMID 29860173 DOI: 10.1016/j.saa.2018.05.104  0.019
2011 Jágerszki G, Takács A, Bitter I, Gyurcsányi RE. Solid-state ion channels for potentiometric sensing Angewandte Chemie - International Edition. 50: 1656-1659. PMID 21308926 DOI: 10.1002/anie.201003849  0.014
2010 Jágerszki G, Grün A, Bitter I, Tóth K, Gyurcsányi RE. Ionophore-gold nanoparticle conjugates for Ag(+)-selective sensors with nanomolar detection limit. Chemical Communications (Cambridge, England). 46: 607-9. PMID 20062877 DOI: 10.1039/b914430g  0.014
2022 Osváth P, Bitter I, Rihmer Z, Balázs J, Vandlik E, Balczár L. [Comments]. Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata. 37: 76-85. PMID 35311700  0.012
2019 Bitter I. [Professor László Tringer has turned 80.] Orvosi Hetilap. 160: 482-483. PMID 30907101 DOI: 10.1556/650.2019.HO2625  0.01
1990 Nemes Z, Volavka J, Bitter I, Laszlo Z. Rhythmic movements of chronic akathisia. Biological Psychiatry. 27: 465-6. PMID 2310800 DOI: 10.1016/0006-3223(90)90563-H  0.01
1984 HERMECZ I, BREINING T, VASVARI-DEBRECZY L, HORVATH A, MESZAROS Z, BITTER I, DEVOS C, RODRIGUEZ L. ChemInform Abstract: NITROGEN BRIDGEHEAD COMPOUNDS. 38. NEW ANTIALLERGIC 4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONES. 3 Chemischer Informationsdienst. 15. DOI: 10.1002/chin.198414248  0.01
Hide low-probability matches.